Diabetic Kidney Disease — Semaglutide Flows into the Mainstream
New England Journal of Medicine · 2024
DOI: 10.1056/nejme2406408 ↗Kurz gefasst
Editorial in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von William G Herrington und 1 weiteren Autor:innen. Beteiligte Einrichtung: From the Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of O…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetic Nephropathies, Hypoglycemic Agents, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
ORCID-Profile: William G Herrington
Zitieren
APA
Herrington, W. G., & Haynes, R. (2024). Diabetic Kidney Disease — Semaglutide Flows into the Mainstream. New England Journal of Medicine. https://doi.org/10.1056/nejme2406408
Vancouver
Herrington WG, Haynes R. Diabetic Kidney Disease — Semaglutide Flows into the Mainstream. New England Journal of Medicine. 2024. doi:10.1056/nejme2406408
BibTeX
@article{Herrington2024,
author = {Herrington, William G and Haynes, Richard},
title = {Diabetic Kidney Disease — Semaglutide Flows into the Mainstream},
journal = {New England Journal of Medicine},
year = {2024},
doi = {10.1056/nejme2406408}
}
EUVIMED